Ublituximab (TG-1101) is a novel glycoengineered anti-CD20 monoclonal antibody
Ublituximab (TG-1101) is a monoclonal antibody that targets CD20 positive B-cells, a component of the body’s immune system. When it attaches to the B-cell it triggers immune reactions (including antibody-dependent cellular cytotoxicity, ADCC, and antibody-dependent cellular phagocytosis that result in the death of the targeted B-cell). Anti-CD20 monoclonal antibodies have proven efficacious in the treatment of diseases in which B-cells have become malignant or overactive, including cancers such as Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) and autoimmune related diseases such as Multiple Sclerosis (MS), Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus(SLE).
While ublituximab is a novel patented molecule, it’s mechanism of action is similar to the approved anti-CD20 monoclonal antibodies. The innovation of ublituximab is that it has been bioengineered to remove certain sugar molecules from the anti-CD20 antibody, which are naturally occurring. By removing the sugar molecules in a process called glycoengineering, we have enhanced the potency of ublituximab with data showing 50-100x greater activity than non-bioengineered anti-CD20 antibodies.
Ublituximab demonstrated encouraging activity as a B-cell depleting agent in early trials, and is now being studied in registration directed clinical trials for patients with CLL and NHL as well as patients with MS.
Please click here to view currently available clinical trials for ublituximab.
Please click here to view our Publications Page for publications and presentations related to ublituximab.